Adoptive transfer of autologous Epstein‐Barr virus–specific cytotoxic T cells for nasopharyngeal carcinoma
暂无分享,去创建一个
K. Yuen | D. Moss | D. Kwong | D. Chua | M. Ng | Bojian Zheng | Jie-fu Huang | J. Sham | See-Yan Lau | W. Luk | S. Im | Bo-jian Zheng
[1] R. Krance,et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation , 1995, The Lancet.
[2] P. Johnson,et al. Enhancement of local control in locally advanced node-positive nasopharyngeal carcinoma by adjunctive chemotherapy. , 1999, International journal of radiation oncology, biology, physics.
[3] S. Knechtle,et al. In Vivo transfer of gene encoding soluble MHC class I prolongs heart transplant survival , 1993 .
[4] I. Ernberg,et al. Expression of epstein‐barr virus‐encoded growth‐transformation‐associated proteins in lymphoproliferations of bone‐marrow transplant recipients , 1991, International journal of cancer.
[5] S. Leung,et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. , 1999, Cancer research.
[6] A. Rickinson,et al. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. , 1997, Journal of immunology.
[7] A Ciechanover,et al. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[8] S Kimbrough,et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. , 1998, Blood.
[9] N. Steven. Epstein–Barr virus latent infection in vivo , 1997, Reviews in medical virology.
[10] J. Reyes,et al. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders , 1997, Journal of clinical microbiology.
[11] R. Martin,et al. CARE-LASS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity. , 1994, Journal of immunological methods.
[12] H. Heslop,et al. Adoptive cellular immunotherapy for EBV lymphoproliferative diseases , 1997 .
[13] S. H. Cheng,et al. Prognostic features and treatment outcome in locoregionally advanced nasopharyngeal carcinoma following concurrent chemotherapy and radiotherapy. , 1998, International journal of radiation oncology, biology, physics.
[14] S. Leung,et al. CTL Control of EBV in Nasopharyngeal Carcinoma (NPC): EBV-Specific CTL Responses in the Blood and Tumors of NPC Patients and the Antigen-Processing Function of the Tumor Cells1 , 2000, The Journal of Immunology.
[15] D. Moss,et al. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. , 1997, Annual review of immunology.
[16] S. Chan,et al. General immunological status of nasopharyngeal carcinoma patients in Singapore. , 1978, IARC scientific publications.
[17] S. Man,et al. Limiting dilution analysis of human T cells: a useful clinical tool. , 1990, Immunology today.
[18] E. Kieff,et al. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies , 1992, The Journal of experimental medicine.
[19] S. Burrows,et al. Identification of cytotoxic T cell epitopes within Epstein‐Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype‐restricted immune recognition of EBV‐infected cells by LMP1‐specific cytotoxic T lymphocytes , 1998, European journal of immunology.
[20] X M Wang,et al. A new microcellular cytotoxicity test based on calcein AM release. , 1993, Human immunology.
[21] S. Groth,et al. The evaluation of limiting dilution assays , 1982 .
[22] F. Zhang,et al. Infiltrating Lymphocytes and Accessory Cells in Nasopharyngeal Carcinoma1 , 1993, Japanese journal of cancer research : Gann.
[23] W. Henle,et al. Epstein‐barr virus‐specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma , 1976, International journal of cancer.
[24] Stefan Imreh,et al. Inhibition of antigen processing by the internal repeat region of the EpsteinBarr virus nuclear antigen-1 , 1995, Nature.
[25] Fazekas de St Groth. The evaluation of limiting dilution assays. , 1982, Journal of immunological methods.
[26] G. Heller,et al. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. , 1996, Blood.
[27] D. Saw,et al. Prognosis and histology in Stage I nasopharyngeal carcinoma (NPC). , 1985, International journal of radiation oncology, biology, physics.
[28] P. Johnson,et al. Staging and IgA VCA titre in patients with nasopharyngeal carcinoma: changes over a 12-year period. , 1998, Oral oncology.
[29] D. Liebowitz. Nasopharyngeal carcinoma: the Epstein-Barr virus association. , 1994, Seminars in oncology.
[30] T. Tursz,et al. Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma , 1992, Journal of virology.
[31] T. Tursz,et al. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. , 1988, The Journal of general virology.
[32] M. Ladanyi,et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. , 1994, The New England journal of medicine.
[33] T. Morishima,et al. Establishment of anti‐Epstein–Barr virus (EBV) cellular immunity by adoptive transfer of virus‐specific cytotoxic T lymphocytes from an HLA‐matched sibling to a patient with severe chronic active EBV infection , 1996, Clinical and experimental immunology.
[34] H. Sack,et al. Carcinoma of the nasopharynx. The significance of lymphocytic infiltration. , 1990, Acta oncologica.
[35] M. Vasef,et al. Nasopharyngeal Carcinoma, with Emphasis on its Relationship to Epstein-Barr Virus , 1997, The Annals of otology, rhinology, and laryngology.
[36] T. Sasagawa,et al. Expression of Epstein-Barr virus in mesopharyngeal and hypopharyngeal carcinomas. , 1999, Human pathology.
[37] Y. W. Zhang,et al. Differences in the growth pattern and clinical course of EBV-LMP1 expressing and non-expressing nasopharyngeal carcinomas. , 1995, European journal of cancer.
[38] J. Mahanta,et al. Aetiology of nasopharyngeal carcinoma. A review. , 1998, Indian journal of cancer.
[39] J. Ho. Stage classification of nasopharyngeal carcinoma: a review. , 1978, IARC scientific publications.
[40] U. Prasad,et al. Analysis of epstein‐barr virus infection in nasopharyngeal biopsies from a group at high risk of nasopharyngeal carcinoma , 2009, International journal of cancer.
[41] H. Wakiguchi,et al. Persistently high Epstein-Barr virus (EBV) loads in peripheral blood lymphocytes from patients with chronic active EBV infection. , 1999, The Journal of infectious diseases.
[42] L. Young,et al. Epstein-Barr virus persistence and virus-associated tumours , 1994, The Lancet.
[43] A. Chan,et al. The significance of keratinizing squamous cell histology in Chinese patients with nasopharyngeal carcinoma. , 1998, Clinical oncology (Royal College of Radiologists (Great Britain)).
[44] Q Y Yao,et al. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts , 1992, Journal of virology.
[45] E. Kieff,et al. Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[46] Malcolm K. Brenner,et al. Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes , 1996, Nature Medicine.
[47] J. Nicholls,et al. Epstein‐Barr virus expression within keratinizing nasopharyngeal carcinoma , 1998, Journal of medical virology.
[48] S. Chan. Aetiology of Nasopharyngeal Carcinoma , 1976, The Lancet.
[49] A. Tanaka,et al. Expression of latent Epstein-Barr virus genomes in human epithelial/Burkitt's lymphoblastoid hybrid cells. , 1978, IARC scientific publications.
[50] H. Heslop,et al. Adoptive cellular immunotherapy for EBV lymphoproliferative disease. , 1997, Immunological reviews.
[51] D. Thorley-Lawson,et al. Detection of the latent form of Epstein-Barr virus DNA in the peripheral blood of healthy individuals , 1996, Journal of virology.
[52] Differential expression of EBER1 in nontumor nasopharyngeal biopsies and nontumor component of nasopharyngeal carcinoma. , 1996, Intervirology.
[53] A. Kumar,et al. Immediate Early and Early Lytic Cycle Proteins Are Frequent Targets of the Epstein-Barr Virus–induced Cytotoxic T Cell Response , 1997, The Journal of experimental medicine.
[54] S. Burrows,et al. Epstein‐Barr virus specific T‐cell response in nasopharyngeal carcinoma patients , 1983, International journal of cancer.
[55] I. Sarov,et al. Significance of Specific Epstein‐Barr Virus IgA and Elevated IgG Antibodies to Viral Capsid Antigens in Nasopharyngeal Carcinoma Patients , 1986, Journal of medical virology.
[56] V. Chong,et al. Carcinoma of the nasopharynx. , 1998, Seminars in ultrasound, CT, and MR.